brings together cardiology, endocrinology & hepatology clinical trialists, industry, regulatory experts, payers, patients representatives and other stakeholders to further advance collective intelligence and foster collaboration about clinical trials through cross-talks.
NASH/MASH: a major unmet need in clinical trial science
it is now clear that non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH/MASH) are a public health problem worldwide.
• It affects around 25-30% of the adult population and causes considerable liver-related and extra-hepatic morbidity and mortality.
• NASH/MASH is considered a metabolic and multi organ disease with cardiovascular complications, worsening metabolic dysfunction and other extra-hepatic diseases, such as type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), or certain extra-hepatic cancers.
